- Home
- CAAP vs ALKS Comparison
CAAP vs ALKS Comparison
Compare CAAP & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAAP | ALKS |
|---|---|---|
| Founded | 1998 | 1987 |
| Country | Luxembourg | Ireland |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.7B |
| IPO Year | 2018 | 1991 |
Fundamental Metrics
Financial Performance| Metric | CAAP | ALKS |
|---|---|---|
| Price | $26.01 | $31.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $25.85 | ★ $42.85 |
| AVG Volume (30 Days) | 138.6K | ★ 1.8M |
| Earning Date | 11-24-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2.44 |
| EPS | 1.09 | ★ 2.02 |
| Revenue | ★ $1,872,934,000.00 | $1,521,338,000.00 |
| Revenue This Year | $5.19 | N/A |
| Revenue Next Year | $7.63 | $22.50 |
| P/E Ratio | $23.84 | ★ $15.72 |
| Revenue Growth | ★ 25.19 | 1.08 |
| 52 Week Low | $15.01 | $25.17 |
| 52 Week High | $27.76 | $36.45 |
Technical Indicators
Market Signals| Indicator | CAAP | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 70.93 |
| Support Level | $25.16 | $28.93 |
| Resistance Level | $27.31 | $31.96 |
| Average True Range (ATR) | 0.78 | 0.94 |
| MACD | -0.20 | 0.38 |
| Stochastic Oscillator | 36.15 | 94.17 |
Price Performance
Historical ComparisonAbout CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops, and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador, and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.